This study is testing a new medication called ERX1000 to see how safe it is and how well people tolerate it when taken for obesity. You might be able to join if you are between 18 and 60 years old, have a Body Mass Index (BMI) between 30 and 50, and your weight has been stable for the past three months. Participants will receive either ERX1000 as a 2mg tablet taken twice weekly, or a placebo (an inactive tablet that looks the same). The main goal is to see how much participants' body weight changes by 12 and 24 weeks. The study plans to enroll 80 men and women, but its current recruitment status is unclear.

Study design

This study is an interventional trial designed to assess the safety and tolerability of ERX1000. It plans to enroll 80 participants who will receive either ERX1000 or a placebo.

What's involved

Participants will take a 2mg tablet (either ERX1000 or placebo) orally twice weekly. The study will measure changes in body weight from enrollment to the end of treatment at Week 24.

Compensation

Not stated in the trial record.

Follow-up

Body weight changes will be measured up to the end of treatment at Week 24.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.